International
Taking the weight loss and diabetes drug semaglutide orally, rather than as an injection, helped patients with diabetes and heart failure to avoid serious outcomes, including hospitalisation, urgent doctor visits and death, according to an analysis of previous trial data. The study found that, compared to placebo, patients with heart failure taking oral semaglutide had a lower risk of a combined outcome of heart failure hospitalisation, urgent heart failure visit or cardiovascular death over a ten month period. The analysis found no significant benefit for these outcomes in people without heart failure to begin with.
Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.
Sign In
